The past decade has witnessed a growing role and increasing use of whole-body magnetic resonance imaging (WB-MRI). Driving these successes are developments in both hardware and software that have reduced overall examination times and significantly improved MR imaging quality. In addition, radiologists and clinicians have continued to find promising new applications of this innovative imaging technique that brings together morphologic and functional characterization of tissues. In oncology, the role of WB-MRI has expanded to the point of being recommended in international guidelines for the assessment of several cancer histotypes (multiple myeloma, melanoma, prostate cancer) and cancer-prone syndromes (Li–Fraumeni and hereditary paraganglioma–pheochromocytoma syndromes). The literature shows growing use of WB-MRI for the staging and follow-up of other cancer histotypes and cancer-related syndromes (including breast cancer, lymphoma, neurofibromatosis, and von Hippel–Lindau syndromes). The main aim of this review is to examine the current scientific evidence for the use of WB-MRI in oncology.
|Titolo:||Whole-body magnetic resonance imaging (WB-MRI) in oncology : recommendations and key uses|
|Parole Chiave:||Cancer screening; Cancer-related syndromes; Diffusion-weighted imaging; Magnetic resonance imaging; Oncology; Whole-body MRI; Radiology, Nuclear Medicine and Imaging|
|Settore Scientifico Disciplinare:||Settore MED/36 - Diagnostica per Immagini e Radioterapia|
|Data di pubblicazione:||mar-2019|
|Data ahead of print / Data di stampa:||nov-2018|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1007/s11547-018-0955-7|
|Appare nelle tipologie:||01 - Articolo su periodico|